| Name | Title | Contact Details |
|---|
InfraScan, Inc. is a medical device company that focuses on developing, commercializing, and distributing hand-held diagnostic devices for head injury and stroke assessment based on near infrared (NIR) technology. The Infrascanner enables clinicians to detect effectively, conveniently, and accurately intracranial bleeding in patients with head trauma. Intracranial hematomas are an important treatable cause of secondary brain injury in patients with head trauma. Recent statistics from Iraq shows that 30% of all wounded in action have head injuries; of them 40% have brain hematomas. Dr. Britton Chance (University of Pennsylvania) and Dr. Claudia Robertson (Baylor College of Medicine) invented a NIR system for detection of brain Hematomas and tested it successfully in 305 patients in Baylor. An entrepreneurial team formed a company around this technology in Collaboration with Drexel University and won the Wharton Business Plan competition in April 2004 and the second prize at the global business plan competition in Singapore in October 2004. Office of Naval Research funded the company in May 2004. The company also attracted $1.5M in funding from BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, from Ben Franklin Technology Partners of Southeastern Pennsylvania, and from Philadelphia Industrial Development Corporation. A multicenter clinical study to support an FDA submission started in July 2006, and on February 2008 an application was submitted to the FDA. After 4 years of review, the FDA cleared Infrascanner Model 1000 as a DeNovo medical technology in December 2011. In January 2013 the FDA cleared the 510(k) of Infrascanner Model 2000.
Hospira is the world`s leading provider of injectable drugs and infusion technologies. Through our broad, integrated portfolio, we are uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. Through our offering of high-quality, lower-cost generic medications, we continue to help reduce the overall costs of healthcare — to improve both the affordability of care for patients and the financial strength of the global healthcare system. By working with our device customers to integrate technologies at the point of care, we are the partner of choice for improving patient and caregiver safety, clinical outcomes, cost management, as well as caregiver efficiency and effectiveness. Additionally, our One2One™ business is a leading provider of contract manufacturing services to proprietary pharmaceutical and biotechnology companies for formulation development, filling and finishing of injectable pharmaceuticals. At Hospira, we have the opportunity to Make a Difference every day by positively impacting the lives of our customers and patients and delivering value to all of our stakeholders.
Xtract Solutions is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
KCBIOMEDIX is a Lenexa, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cutera was established in the San Francisco Bay Area (Brisbane) in 1998 by veteran laser and optical engineers. As the pioneer of Nd:YAG technology, CUTERA® is the trusted authority in Face + Body energy-based medical aesthetic technologies that practitioners around-the-world turn to for innovation, sophistication and performance. At Cutera, we`re always looking forward; developing new solutions, products and industry-leading services designed around the needs of medical aesthetic community—delivering better results, faster and safer than ever before. CUTERA`s premium portfolio of products include: xeo®, truSculpt® and excel V™. In 2014, CUTERA introduced two new exciting additions to their family of premium products: excel HR™ for high-speed, comfortable, hair removal and enlighten™, the industry`s first Picosecond + Nanosecond + 2 Wavelength High-Powered laser system. Today, our worldwide presence is represented in 40 countries, with direct operations in North America, France, Australia, Belgium, the Netherlands and Luxembourg.